We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+14.95%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.78B
AUM Growth
-$802M
Cap. Flow
-$1.61B
Cap. Flow %
-18.35%
Top 10 Hldgs %
33.27%
Holding
157
New
20
Increased
27
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$131M
2
MRK icon
Merck
MRK
+$97.5M
3
EW icon
Edwards Lifesciences
EW
+$97.4M
4
AGN.PRA
Allergan plc
AGN.PRA
+$76.2M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$72.9M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$213M
2
BMY icon
Bristol-Myers Squibb
BMY
+$184M
3
ABBV icon
AbbVie
ABBV
+$152M
4
BSX icon
Boston Scientific
BSX
+$141M
5
AGN
Allergan plc
AGN
+$138M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Financials 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBRV
101
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$9.27M 0.11%
5,260
– –
SYRE icon
102
Spyre Therapeutics
SYRE
$8.35B
$8.72M 0.1%
54,409
– –
CLLS
103
Cellectis
CLLS
$287M
$8.43M 0.1%
350,000
– –
PTLA
104
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$8.42M 0.1%
370,900
– –
SIEN
105
DELISTED
Sientra, Inc.
SIEN
$8.25M 0.09%
91,750
-44,000
-32% -$3.42M
NUVA
106
DELISTED
NuVasive, Inc.
NUVA
$8.23M 0.09%
123,500
-123,600
-50% -$7.87M
XENE icon
107
Xenon Pharmaceuticals
XENE
$6.18B
$8.1M 0.09%
+1,000,000
New +$7.72M
NERV icon
108
Minerva Neurosciences
NERV
$195M
$7.85M 0.09%
69,525
+29,337
+73% +$2.85M
RDHL
109
Redhill Biopharma
RDHL
$4.26M
$7.85M 0.09%
565
– –
BMY icon
110
CALL
Bristol-Myers Squibb
BMY
$130B
$5.39M 0.06%
+100,000
New +$6.42M
ADAP
111
DELISTED
Adaptimmune Therapeutics
ADAP
$5.11M 0.06%
724,184
– –
INFI
112
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$5.07M 0.06%
3,250,300
– –
GWPH
113
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$4.8M 0.05%
+36,200
New +$3.46M
BHC icon
114
Bausch Health
BHC
$1.7B
$4.79M 0.05%
194,900
– –
NVTA
115
DELISTED
Invitae Corporation
NVTA
$4M 0.05%
456,666
– –
SGMO
116
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.85M 0.04%
+831,500
New +$4.23M
QURE icon
117
uniQure
QURE
$2.74B
$3.74M 0.04%
489,000
+293,600
+150% +$2.33M
AMED
118
DELISTED
Amedisys
AMED
$3.39M 0.04%
71,500
+51,500
+258% +$2.57M
ROKA
119
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$2.24M 0.03%
322,043
– –
CGNT
120
DELISTED
Cogentix Medical, Inc.
CGNT
$1.6M 0.02%
878,145
-112,600
-11% -$146K
ITCI
121
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.37M 0.02%
+90,000
New +$3.64M
BLRX
122
BioLineRX
BLRX
$12.3M
$1.19M 0.01%
1,731
– –
AMRN
123
Amarin Corp
AMRN
$300M
$1.12M 0.01%
17,500
– –
MRNS
124
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.03M 0.01%
141,900
-75,000
-35% -$507K
QLTI
125
DELISTED
QLT Inc
QLTI
$1.03M 0.01%
500,000
– –
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2016 Portfolio in Review

As of Q3 2016, OrbiMed held 157 positions worth $8.78B, down 8.4% from $9.58B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed withdrew a net $1.61B in Q3 2016, closing 17 positions and reducing 40 holdings. Its most notable exit was RELYPSA INC COM, an estimated $137M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Allergan plc worth $72.5M.

  • OrbiMed's largest Q3 2016 buy was Allergan plc: 88,200 shares worth $72.5M.
  • OrbiMed added most to Shire pic in Q3 2016, an estimated $131M increase.
  • OrbiMed's biggest Q3 2016 reduction was HCA Healthcare, cutting an estimated $213M.
  • OrbiMed fully exited RELYPSA INC COM in Q3 2016, selling an estimated $137M.
  • OrbiMed's ten largest holdings make up 33% of its $8.78B portfolio in Q3 2016.
  • OrbiMed opened 20 new positions and closed 17 in Q3 2016.
  • OrbiMed's portfolio value fell 8.4% quarter-over-quarter to $8.78B.

Based on OrbiMed's 13F filing for Q3 2016, filed 14 Nov 2016.